SCHEMBL4819935

SCHEMBL4819935

CCOc1c(F)c(F)c(-c2c(Cl)nc3ncnn3c2NC2CCCC2)c(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.32
CDK2 P24941 1/20 0.32
GSK3B P49841 1/20 0.32
PDE2A O00408 1/20 0.31
HPGD P15428 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
GAA P10253 2/20 0.31
ALDH1A1 P00352 1/20 0.31
RAB9A P51151 1/20 0.31
ATM Q13315 1/20 0.30
MAPK1 P28482 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816384 0.86 CDK2 (0.35) TSHRSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL7487750 0.80 MAPK1 (0.37) TSHRSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL7490009 0.79 KMT2A (0.38) TSHRSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL7496989 0.79 KMT2A (0.38) TSHRSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL978477 0.79 KMT2A (0.36) TSHRSMN1; SMN2KMT2AMEN1CDK2
SCHEMBL4819367 0.79 PDE2A (0.38) TSHRSMN1; SMN2KMT2ACDK2GSK3B
SCHEMBL7958939 0.77 CDK2 (0.38) TSHRSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL4817675 0.76 LMNA (0.39) TSHRSMN1; SMN2KMT2ALMNACDK2
SCHEMBL5227382 0.76 MEN1 (0.47) TSHRSMN1; SMN2KMT2ALMNAMEN1
SCHEMBL7490647 0.76 EGLN2 (0.39) TSHRSMN1; SMN2KMT2APOLBCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US claimed
EP-1307200-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS Wyeth (US) 2003-05-07 EP claimed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US claimed
WO-2002002563-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS WYETH (US) 2002-01-10 WO claimed
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US disclosed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents TUBB3, TUBA1C, TUBB1 TSHR 2567/4885SMN1; SMN2 655/4885KMT2A 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.